Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

anthrax/ödem

Länken sparas på Urklipp
10 resultat

Monoclonal antibodies that neutralize anthrax toxins

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION This invention relates generally to the field of immunology and specifically to monoclonal antibodies that bind and/or neutralize anthrax lethal factor (LF) or edema factor (EF). REFERENCE TO SEQUENCE LISTING, TABLE, OR COMPUTER PROGRAM LISTING The present application is being

Monoclonal antibodies that neutralize anthrax toxins

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION This invention relates generally to the field of immunology and specifically to monoclonal antibodies that bind and/or neutralize anthrax lethal factor (LF) or edema factor (EF). REFERENCE TO SEQUENCE LISTING, TABLE, OR COMPUTER PROGRAM LISTING The present application is being

Monoclonal antibodies that neutralize anthrax toxins

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION This invention relates generally to the field of immunology and specifically to monoclonal antibodies that bind and/or neutralize anthrax lethal factor (LF) or edema factor (EF). REFERENCE TO SEQUENCE LISTING, TABLE, OR COMPUTER PROGRAM LISTING The present application is being

Monoclonal antibodies that neutralize anthrax toxins

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
REFERENCE TO SEQUENCE LISTING This application contains a Sequence Listing submitted as an electronic text file named "NIH352.sub.--001VPC_SEQ_LISTING.TXT", having a size in bytes of 98 KB, and created on Aug. 24, 2009. The information contained in this electronic file is hereby incorporated by

Monoclonal antibodies that neutralize anthrax toxins

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION This invention relates generally to the field of immunology and specifically to monoclonal antibodies that bind and/or neutralize anthrax lethal factor (LF) or edema factor (EF). REFERENCE TO SEQUENCE LISTING This application contains a Sequence Listing submitted as an

Targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION The present invention relates generally to the fields of bacteriology, immunology, and vaccine technology. The present invention also relates to Bacillus anthracis proteins as novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure

Anthrax compositions and methods of use and production

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD The present invention relates to the field of immunology and more particularly relates to methods and compositions for treating, preventing or reducing anthrax infection in humans or animals. BACKGROUND OF THE INVENTION Anthrax is a disease caused by the sporulating bacteria Bacillus

Process for the preparation of non-toxic anthrax vaccine

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION This invention relates to a Recombinant DNA construct and a process for the preparation of a nontoxic anthrax vaccine. BACKGROUND OF THE INVENTION Anthrax, a zoonotic disease is caused by gram-positive, sporulating bacteria, Bacillus anthracis. Humans are accidental hosts

Methods and compositions relating to anthrax pathogenesis

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION The present invention generally relates to crystalline Edema Factor (EF) without substrate, crystalline Edema Factor-calmodulin complex without substrate and the structures of Edema Factor without substrate and Edema Factor-calmodulin complex as determined by x-ray

Rapid immunoassay of anthrax protective antigen in vaccine cultures and bodily fluids by fluorescence polarization

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION The inventive subject matter relates to a competitive fluorescence method for estimating the concentration in a sample of Bacillus anthracis protein or specific antibody. The method contemplates the use of FLT, FRET or FP. BACKGROUND OF INVENTION Oral fluids have been
Gå med på vår
facebook-sida

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

  • Fungerar på 55 språk
  • Växtbaserade botemedel som stöds av vetenskap
  • Örter igenkänning av bild
  • Interaktiv GPS-karta - märka örter på plats (kommer snart)
  • Läs vetenskapliga publikationer relaterade till din sökning
  • Sök efter medicinska örter efter deras effekter
  • Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning

Google Play badgeApp Store badge